Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Preparation and in vitro Studies of [125-I]IUDR-T101 Antibody Conjugate



M C. Chakrabarti, C H. Paik, J A. Carrasquillo


Idoxuridine labeled with 125I was conjugated to polylysine. This conjugate was then coupled to the carbohydrate side chains of T101 monoclonal antibodiy (anti-CD5). The immunoreactivity, cell retention, cytotoxicity, and intracellular localization of this conjugate was tested in CCRF-CEM cells (CD5 positive). The conjugate had 68 % immunoreactivity. The retention of 125I by CCRF-CEM cells was higher for the conjugate than for T101 directly labeled with 125I and more of it localized in the nucleus than did the 125I-labeled T101. The 125I IUDR-polylysine-T101 conjugate was more cytotoxic than the 125I-labeled T101. In conclusion, the conjugation of [125I]IUDR to T101 is feasible, and preferential targeting of the 125I to the nucleus is obtained.
Cancer Biotherapy and Radiopharmaceuticals
No. 2


CD5, endocytosis, iodine, IUDR, monoclonal antibody


Chakrabarti, M. , Paik, C. and Carrasquillo, J. (2000), Preparation and in vitro Studies of [<sup>125</sup>-I]IUDR-T101 Antibody Conjugate, Cancer Biotherapy and Radiopharmaceuticals (Accessed June 18, 2024)


If you have any questions about this publication or are having problems accessing it, please contact

Created January 1, 2000, Updated February 17, 2017